- Home
- TNDM vs CLDX Comparison
TNDM vs CLDX Comparison
Compare TNDM & CLDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNDM
- CLDX
- Stock Information
- Founded
- TNDM 2006
- CLDX 1983
- Country
- TNDM United States
- CLDX United States
- Employees
- TNDM N/A
- CLDX N/A
- Industry
- TNDM Medical/Dental Instruments
- CLDX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- TNDM Health Care
- CLDX Health Care
- Exchange
- TNDM Nasdaq
- CLDX Nasdaq
- Market Cap
- TNDM 1.9B
- CLDX 1.6B
- IPO Year
- TNDM 2013
- CLDX 2008
- Fundamental
- Price
- TNDM $35.15
- CLDX $23.78
- Analyst Decision
- TNDM Buy
- CLDX Buy
- Analyst Count
- TNDM 16
- CLDX 7
- Target Price
- TNDM $52.06
- CLDX $64.83
- AVG Volume (30 Days)
- TNDM 1.1M
- CLDX 1.1M
- Earning Date
- TNDM 02-26-2025
- CLDX 02-24-2025
- Dividend Yield
- TNDM N/A
- CLDX N/A
- EPS Growth
- TNDM N/A
- CLDX N/A
- EPS
- TNDM N/A
- CLDX N/A
- Revenue
- TNDM $854,351,000.00
- CLDX $9,976,000.00
- Revenue This Year
- TNDM $23.98
- CLDX N/A
- Revenue Next Year
- TNDM $10.89
- CLDX N/A
- P/E Ratio
- TNDM N/A
- CLDX N/A
- Revenue Growth
- TNDM 10.75
- CLDX 128.55
- 52 Week Low
- TNDM $21.85
- CLDX $22.17
- 52 Week High
- TNDM $53.69
- CLDX $53.18
- Technical
- Relative Strength Index (RSI)
- TNDM 48.69
- CLDX 41.99
- Support Level
- TNDM $34.51
- CLDX $22.17
- Resistance Level
- TNDM $38.28
- CLDX $29.05
- Average True Range (ATR)
- TNDM 1.78
- CLDX 1.57
- MACD
- TNDM -0.22
- CLDX -0.26
- Stochastic Oscillator
- TNDM 20.76
- CLDX 23.40
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.
About CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140,CDX-0159/Anti-KIT Program, and CDX-527.